Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease Clinical Trial

Official title:

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00295165
• Other study ID #: 310187
• Secondary ID: 91494NOVEL8
• Status: Terminated
• Phase: Phase 3
• First received: February 21, 2006
• Last updated: December 2, 2013
• Start date: January 2006
• Est. completion date: October 2006

Study information

• Verified date: December 2013
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods AdministrationBrazil: Ministry of HealthBulgaria: Bulgarian Drug AgencyCanada: Health CanadaIsrael: Israeli Health Ministry Pharmaceutical AdministrationRomania: National Medicines AgencyRussia: Pharmacological Committee, Ministry of HealthSouth Africa: Medicines Control CouncilUkraine: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.

Description:

On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

Other known NCT identifiers

• NCT00295321

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 33
• Est. completion date: October 2006
• Est. primary completion date: October 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent

2. Male or female, age >/= 18 years

3. Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at least 4 months prior to receiving the first dose of study drug

4. Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater than or equal to 220 and less than or equal to 475 points)

5. If under treatment for Crohn's disease, medication must be stable for at least 4 weeks prior to receiving the first dose of study drug. The following therapies are allowed:

• Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or balsalazide) for Crohn's disease

• Antibiotics or probiotics for Crohn's disease

• Topical rectal therapy with mesalamine

6. Females of child-bearing potential:

Negative pregnancy test within 72 hours prior to receiving the first dose of study drug

7. Sexually-active males and females of child-bearing potential:

Agreement to use adequate method of contraception throughout the study

8. Ability to self-inject study drug or availability of a designee who can do so

Exclusion Criteria:

1. Pregnancy or breast-feeding

2. Colostomy or ileostomy

3. Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage

4. GI surgery within 6 months prior to receiving the first dose of study drug

5. Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected

6. Positive stool test results for any of the following:

Bacteria:

• Salmonella spec.

• Shigella spec.

• Campylobacter spec.

Bacterial toxin:

• Clostridium difficile

Ova and parasites:

• Amoeba spec.

• Giardia spec.

• Cryptosporidium spec.

7. Any of the following laboratory abnormalities:

• Serum creatinine >/= 2.0 mg/dL

• Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin >/=; 2 x the upper limit of normal

• Hemoglobin (Hgb) < 8.0 g/dL

• Absolute neutrophil count (ANC) </= 1,000 cells/µL or > cells 20,000/µL

8. Planned in-patient hospitalization during the study

9. Presence or history of cancer of any type (except treated basal cell carcinoma) or definite dysplasia of the colon within the last 5 years

10. Use of any of the following medications during the specified period of time prior to receiving the first dose of study drug:

At any time:

• Recombinant human GM CSF (sargramostim or molgramostim)

• Granulocyte colony-stimulating factor (G CSF; filgrastim or pegfilgrastim)

• Natalizumab 8 weeks: or 5 half-lives (whichever is longer)

• Licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy such as infliximab or adalimumab 4 weeks:

• 6-mercaptopurine

• Azathioprine

• Cyclophosphamide

• Methotrexate

• Mycophenolate mofetil

• Tacrolimus

• Cyclosporine

• Thalidomide

• Glucocorticoids, including budesonide and prednisone, or local glucocorticoid therapy for Crohn's disease

• Any other immunosuppressive drugs

11. Use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug

12. Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental or semi-elemental diets) within 4 weeks prior to receiving the first dose of study drug. If the physician judges that nutritional supplementation is needed, enteral nutritional supplements will be allowed for patients who have been receiving a stable regimen for at least 4 weeks prior to receiving the first dose of study drug and that is intended to continue through the 8 week treatment period.

13. History of allergy to yeast products or to sargramostim or to any other excipient of the study drug formulation

14. Active drug or alcohol abuse

15. Clinically important co-morbid conditions unrelated to Crohn's disease as determined by the investigator

16. Previous randomization into this study, or into any other study of the sponsor's sargramostim development program

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Crohn Disease

Intervention

Drug:
• Sargramostim (Leukine)
Sargramostim 6 mcg/kg subcutaneously once daily
• Placebo
Placebo subcutaneously once daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Bulgaria,  Canada,  Israel,  New Zealand,  Romania,  Russian Federation,  South Africa,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To induce clinical remission and/or clinical response following 8 weeks of treatment		8 weeks
Secondary	To assess the safety profile of sargramostim (including development of antibodies against sargramostim)		During study treatment
Secondary	To assess quality of life (QoL)		During study treatment

External Links

•   Click here and search for drug information provided by the FDA
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product